/TLPH
TLPH Stock - Talphera, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$1.10-0.90%
$0.01 (-0.90%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.60
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.21
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TLPH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.09 – $1.11
TARGET (TP)$1.26
STOP LOSS$1.01
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.25
52W High$1.57
52W Low$0.38
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $651,000 | N/A | $378,000 | $5.42M |
| Gross Profit | $-6,718,000 | $-4,895,000 | $-1,647,000 | $-2,628,000 | $-616,000 |
| Gross Margin | N/A | -751.9% | N/A | -695.2% | -11.4% |
| Operating Income | $-15,252,000 | $-16,889,000 | $-20,352,000 | $-18,116,000 | $-40,963,000 |
| Net Income | $-13,004,000 | $-18,397,000 | $42.52M | $-35,099,000 | $-40,379,000 |
| Net Margin | N/A | -2826.0% | N/A | -9285.4% | -745.6% |
| EPS | $-0.50 | $-1.29 | $5.73 | $-5.86 | $-9.47 |
Company Overview
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$4
Average Target
↑ 263.6% Upside
Now
$4
Low
$4
Average
$4
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 28th 2025 | Rodman & Renshaw | Initiation | Buy | $4 |
Earnings History & Surprises
TLPHBeat Rate
93%
Last 14 quarters
Avg Surprise
+77.7%
EPS vs Estimate
Beats / Misses
13/1
Last 12 quarters
Latest EPS
$-0.11
Q4 2025
EPS Surprise History
Q4 23
+71.4%
$-0.08vs$-0.28
Q2 24
+42.9%
$-0.16vs$-0.28
Q3 24
+31.8%
$-0.15vs$-0.22
Q4 24
+35.0%
$-0.13vs$-0.20
Q1 25
+66.7%
$-0.07vs$-0.21
Q2 25
+5.9%
$-0.16vs$-0.17
Q3 25
+16.7%
$-0.10vs$-0.12
Q4 25
-46.7%
$-0.11vs$-0.07
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.07 | $-0.11 | -46.7% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.12 | $-0.10 | +16.7% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.17 | $-0.16 | +5.9% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-0.21 | $-0.07 | +66.7% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.20 | $-0.13 | +35.0% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.22 | $-0.15 | +31.8% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.28 | $-0.16 | +42.9% | ✓ BEAT |
Q4 2023 | Dec 6, 2023 | $-0.28 | $-0.08 | +71.4% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.29 | $-0.08 | +72.4% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.53 | $-0.41 | +22.6% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-0.79 | $-0.75 | +4.7% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | — | $-1.00 | — | — |
Q3 2022 | Sep 30, 2022 | $-1.20 | $-0.91 | +23.8% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | $-1.50 | $9.60 | +740.0% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | $-1.20 | $-1.19 | +0.7% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $-1.24 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-1.40 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-1.65 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-1.58 | — | — |
Latest News
Talphera shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Nov 13, 2025, 02:18 PM
Talphera Q3 EPS $(0.11) Beats $(0.13) Estimate, Sales $1.000K
📈 PositiveBenzinga•Nov 12, 2025, 09:07 PM
Talphera Granted CorMedix Exclusive Right Of First Negotiation For Potential Acquisition Of Co. With 60 Day Exclusive Negotiation Period Following Completion And Announcement Of Phase 3 Niyad Study Results And Right To Nominate One Member To Talphera's Board
📈 PositiveBenzinga•Sep 8, 2025, 12:37 PM•Also:
Talphera shares are trading higher after CorMedix made a $5M minority investment, purchasing 9,090,909 shares at $0.55 each.
📈 PositiveBenzinga•Sep 8, 2025, 12:33 PM•Also:
CorMedix Makes $5M Minority Investment In Talphera Of 9,090,909 Shares At $0.55/Share
➖ NeutralBenzinga•Sep 8, 2025, 12:31 PM•Also:
Talphera Enrolls 17 Patients In 70-Patient NEPHRO CRRT Pivotal Trial
➖ NeutralBenzinga•Aug 25, 2025, 12:33 PM
Talphera Cuts Expenses 14 Percent
📈 PositiveThe Motley Fool•Aug 14, 2025, 09:43 PM
Talphera Cuts Costs and Speeds Trial
📈 PositiveThe Motley Fool•Aug 14, 2025, 09:19 PM
Frequently Asked Questions about TLPH
What is TLPH's current stock price?
Talphera, Inc. (TLPH) is currently trading at $1.10 per share. The stock has moved -0.90% today.
What is the analyst price target for TLPH?
No analyst price targets are currently available for this stock.
What sector is Talphera, Inc. in?
Talphera, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is TLPH's market cap?
Talphera, Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does TLPH pay dividends?
No, Talphera, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPUS
Apimeds Pharmaceuticals US, Inc
$1.52
Mkt Cap: $0.0B
COSM
Cosmos Health Inc.
$0.49
Mkt Cap: $0.0B
IBIO
iBio, Inc.
$1.98
Mkt Cap: $0.0B
INTS
Intensity Therapeutics, Inc.
$0.41
Mkt Cap: $0.0B
ITRM
Iterum Therapeutics plc
$0.37
Mkt Cap: $0.0B
MIRA
MIRA Pharmaceuticals, Inc.
$1.63
Mkt Cap: $0.1B
NTRB
Nutriband Inc.
$4.49
Mkt Cap: $0.1B
PIII
P3 Health Partners Inc.
$4.12
Mkt Cap: $0.0B
RVP
Retractable Technologies, Inc.
$0.82
Mkt Cap: $0.0B
SCYX
SCYNEXIS, Inc.
$0.63
Mkt Cap: $0.0B
Explore stocks similar to TLPH for comparison